


MAY 19 1999

Dade Behring Inc.
N/T Protein Control SL
510(k) Notification

 K991182

510(k) Summary For N/T Protein Control SL

1. Manufacturer's Name, Address, Telephone, and Contact Person, Date of Preparation:

Manufacturer: Dade Behring Marburg GmbH
Emil-von-Behring Str. 76
Marburg/Germany

Contact Information: Dade Behring Inc.
Glasgow Site
P.O. Box 6101
Newark, Delaware 19714
Attn: Carolyn K. George
Tel: 302-631-6283

Preparation date: April 5, 1999

2. Device Name/ Classification:

N/T Protein Control SL: Quality Control Material (assayed)

Classification Number: Class I (862.1660)

3. Identification of the Legally Marketed Device:

N/T Protein Control SL (K964065)

4. Device Description:

N/T Protein Control SL is a liquid control prepared from human serum with stabilizers and preservative. It is intended to be used as an accuracy and precision control for the determination of human serum proteins by immunonephelometry with the Behring Nephelometer Systems and by immunoturbidimetry with the TurbiTimeSystem.

5. Device Intended Use:

N/T Protein Controls SL/L, M, and H are for use as accuracy and precision controls in the determination of the following human serum proteins by immunonephelometry with the Behring Nephelometer Systems: IgG, IgG₁₋₄, IgA, IgM, C3c, C4, Transferrin, Albumin, α_1 -antitrypsin, α_2 -macroglobulin, Haptoglobin, α_1 -acid glycoprotein, Prealbumin, Ceruloplasmin, RbP, Ig/L-chain lambda & kappa, β_2 -microglobulin, Soluble transferrin receptor (sTfR), Ferritin, IgE; and, by immunoturbidimetry with the TurbiTimeSystem: IgG, IgG₁₋₄, IgA, IgM, C3c, C4, Transferrin, Albumin, Haptoglobin, α_1 -acid glycoprotein. The controls can also be used for quality control in the Total Protein assay, using the Behring Nephelometer Systems.

000009

6. Medical device to which equivalence is claimed and comparison information:

The N/T Protein Control SL (modified to include sTfR) is substantially equivalent in intended use to the N/T Protein Control SL (K964065) currently marketed. The N/T Control SL (modified), like the current N/T Protein Control SL is intended to be used as quality control material to monitor the accuracy and precision of human serum protein assays on the Behring Nephelometer Systems and TurbiTimeSystem.

7. Device Performance Characteristics:

Stability:

Stability was evaluated according to in-house protocols and the control was found to be stable for at least 12 months at +2° to +8° C, as originally packaged and for at least 14 days at +2° to +8° C, once opened.



DEPARTMENT OF HEALTH & HUMAN SERVICES

MAY 19 1999

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Carolyn K. George
Manager, Regulatory Affairs, Biology
Dade Behring Inc.
P.O. Box 6101
Newark, Delaware 19714

Re: K991182
Trade Name: N/T Protein Control SL: Quality Control Material
Regulatory Class: I
Product Code: JJY
Dated: April 5, 1999
Received: April 7, 1999

Dear Ms. George :

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D, M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

